Consensus Waters Corporation Sao Paulo

Stocks

WATC34

BRWATCBDR009

Advanced Medical Equipment & Technology

Market Closed - Sao Paulo 15:26:43 08/06/2026 BST			5-day change	1st Jan Change
476.58 ^BRL	+11.39%		-.--%	-9.22%

09-16	Everlywell Announces Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. to Patients	CI
09-14	Waters Corporation Announces Global Commercial Launch of BD FACSDiscover A7 Cell Analyzer	CI

efd6964ae7977f5.bgJQENqpHUbueFV6B7MuvmPKO9_XZmIMqwbT7kGzzM0.JFEDJozPLxbXMzIefdlg5FSbc46vUFtW-UemnC3H4bovcD5J98JkIt8-ZQ~e85e5e5ed8000059c0a1589abfc3cb66

Analysts' recommendations: Waters Corporation

09-09	UBS Upgrades Waters to Buy From Neutral, Adjusts Price Target to $490 From $375	MT
09-03	Baird Adjusts Price Target on Waters to $456 From $434, Keeps Outperform Rating	MT
09-01	HSBC Adjusts Price Target on Waters to $455 From $450, Maintains Buy Rating	MT
08-27	Waters Shares Rise After Piper Sandler Upgrade	MT
08-27	Piper Sandler Upgrades Waters to Overweight From Neutral, $480 Price Target	MT
08-27	Analyst recommendations: Block, Celsius, Crowdstrike, Gitlab, Nvidia…
08-24	Waters' Q4 Guide Conservative, 2027 Growth Could Reach High Single Digits, RBC Says	MT
08-05	Goldman Sachs Adjusts Waters Price Target to $465 From $425	MT
08-05	JPMorgan Adjusts Waters Price Target to $400 From $370	MT
08-05	Wells Fargo Adjusts Waters Price Target to $400 From $370	MT
08-05	Stifel Nicolaus Adjusts Waters Price Target to $420 From $380	MT
08-05	RBC Capital Adjusts Waters Price Target to $475 From $435, Maintains Outperform Rating	MT
08-05	Deutsche Bank Adjusts Waters Price Target to $400 From $380, Maintains Hold Rating	MT
08-05	Barclays Adjusts Price Target on Waters to $460 From $425, Maintains Overweight Rating	MT
08-05	Evercore ISI Adjusts Price Target on Waters to $420 From $410, Maintains Outperform Rating	MT
08-05	Leerink Partners Adjusts Price Target on Waters to $450 From $420, Maintains Outperform Rating	MT
08-05	Bernstein Adjusts Price Target on Waters to $450 From $435, Maintains Outperform Rating	MT
08-05	Jefferies Adjusts Price Target on Waters to $455 From $450, Maintains Buy Rating	MT
08-05	TD Cowen Upgrades Waters to Buy From Hold, Adjusts Price Target to $475 From $408	MT
07-15	TD Cowen Adjusts Price Target on Waters to $408 From $385, Keeps Hold Rating	MT
07-14	Goldman Sachs Adjusts Price Target on Waters to $425 From $380, Maintains Buy Rating	MT
07-13	Baird Adjusts Price Target on Waters to $418 From $387, Maintains Outperform Rating	MT
07-09	Morgan Stanley Adjusts Price Target on Waters to $390 From $350	MT
07-09	Waters Seen Benefiting From BD Turnaround, Pharma Manufacturing Tailwinds, RBC Says	MT
07-09	RBC Capital Initiates Waters at Outperform With $435 Price Target	MT

More recommendations

Other Advanced Medical Equipment & Technology

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
WATERS CORPORATION	-	-	-	-
THERMO FISHER SCIENTIFIC, INC.				-0.97%
DANAHER CORPORATION				+8.16%
INTUITIVE SURGICAL, INC.				+21.11%
BOSTON SCIENTIFIC CORPORATION				+42.5%
EDWARDS LIFESCIENCES CORPORATION				+14.39%
SIEMENS HEALTHINEERS AG				+20.52%
AGILENT TECHNOLOGIES, INC.				+11.81%
WATERS CORPORATION				+5%
ILLUMINA, INC.				-15.43%
Average				+11.90%
Weighted average by Cap.				+10.43%